Anti-cancer
Olaparib
CAS No.
763113-22-0
A PARP inhibitor used in oral oncology formulations for BRCA-mutated ovarian, breast, pancreatic, and prostate cancers.
Olaparib is a targeted PARP-inhibitor oncology API manufactured by NovaAcura Biotech under GMP-compliant conditions. Full batch documentation and regulatory support are available for global oncology formulation partners.
Applications & Uses
A PARP inhibitor used in oral oncology formulations for BRCA-mutated ovarian, breast, pancreatic, and prostate cancers.
Full technical documentation, batch specifications and regulatory support (DMF/CEP) are available on request.
Need This Molecule at Scale?
Get in touch for pricing, lead times and full regulatory documentation.
Get In Touch